Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
News|Podcasts|October 19, 2026

The BioPharm Brief: New Approval, Pediatric Progress, and Durable Remission

The FDA grants accelerated approval to dostarlimab for rectal cancer, Lilly reports one-year remission data for pediatric ulcerative colitis, and Johnson & Johnson shares longer-term fistula remission results for Tremfya.

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry. We're looking at a new FDA approval for rectal cancer, encouraging results in children with ulcerative colitis, and longer-term data for a difficult complication of Crohn disease.

First, GSK's Jemperli has received FDA accelerated approval for certain adults with locally advanced rectal cancer. The treatment is for patients whose tumors have specific genetic features known as M-S-I-high or mismatch repair deficient. In the phase 2 AZUR-1 trial, 68% of evaluable patients maintained a complete clinical response at 12 months. For eligible patients, the treatment could offer an alternative to the traditional combination of chemotherapy, radiation, and surgery. The accelerated approval means further research is needed to confirm the treatment's long-term benefits.

Next, Eli Lilly's Omvoh has delivered one-year remission results in children and adolescents with ulcerative colitis. In the phase 3 SHINE-2 trial, half of the patients who initially responded to treatment were in clinical remission at week 52. Half also achieved remission without needing corticosteroids, a class of anti-inflammatory drugs. More than half of the patients enrolled had previously not responded adequately to a biologic treatment. Lilly plans to submit the findings to regulators to support a potential pediatric label expansion. Omvoh is already approved for adults with ulcerative colitis and Crohn disease.

And Johnson & Johnson's Tremfya has shown continued improvement in fistula remission in adults with Crohn disease. In the phase 3 FUZION study, 28% of patients receiving one maintenance dosing regimen had remission of their fistulas at week 24. By week 48, that figure had risen to 35%. Fistulas are abnormal connections that can form between the bowel and nearby areas of the body, and they can be particularly difficult to treat in people with Crohn disease. The findings offer a longer-term look at Tremfya's potential to help patients manage this complication.

That’s today’s BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key takeaways

  • FDA approval: Dostarlimab offers a new treatment option for eligible patients with biomarker-defined locally advanced rectal cancer.
  • Pediatric IBD: Half of the pediatric patients who initially responded to Omvoh achieved clinical remission at one year.
  • Longer-term results: Tremfya maintained or improved fistula remission through 48 weeks in the phase 3 FUZION study.

Related to this article

View more
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
Read more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more